BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19:2786-2794. [PMID: 20810605 DOI: 10.1158/1055-9965.epi-10-0667] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011;17:4091-100. [PMID: 21527562 DOI: 10.1158/1078-0432.CCR-10-2579] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
2 Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, Song BJ, Park JM, Yoon YB. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977. [PMID: 24250822 DOI: 10.1371/journal.pone.0078977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
3 Breitkopf CR, Sinicrope PS, Rabe KG, Brockman TA, Patten CA, McWilliams RR, Ehlers S, Petersen GM. Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. Hered Cancer Clin Pract. 2012;10:8. [PMID: 22738386 DOI: 10.1186/1897-4287-10-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
4 Shin EJ, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am. 2012;41:143-157. [PMID: 22341255 DOI: 10.1016/j.gtc.2011.12.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
5 Muhammad W, Hart GR, Nartowt B, Farrell JJ, Johung K, Liang Y, Deng J.   Pancreatic cancer prediction through an artificial neural network. Frontiers in Artificial Intelligence 2019; 2: 2. [PMID: 33733091 DOI: 10.3389/frai.2019.00002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
6 Gold DV, Newsome G, Liu D, Goldenberg DM. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer 2013;12:143. [PMID: 24257318 DOI: 10.1186/1476-4598-12-143] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
7 Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Lacroix A, Li D, Mandelson MT, Olson SH, Petersen GM, Risch HA, Stolzenberg-Solomon RZ, Zheng W, Amundadottir L, Albanes D, Allen NE, Bamlet WR, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, Duell EJ, Elena J, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hassan M, Hutchinson A, Hunter DJ, Kooperberg C, Kurtz RC, Liu S, Overvad K, Palli D, Patel AV, Rabe KG, Shu XO, Slimani N, Tobias GS, Trichopoulos D, Van Den Eeden SK, Vineis P, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hoover RN, Hartge P, Kraft P. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One 2013;8:e72311. [PMID: 24058443 DOI: 10.1371/journal.pone.0072311] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
8 Chhatrala R, Thanavala Y, Iyer R. Targeted therapy in gastrointestinal malignancies. J Carcinog 2014;13:4. [PMID: 24737952 DOI: 10.4103/1477-3163.127639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 2013;119:522-8. [PMID: 22898932 DOI: 10.1002/cncr.27762] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
10 Manne A, Esnakula A, Abushahin L, Tsung A. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:3059. [PMID: 34205412 DOI: 10.3390/cancers13123059] [Reference Citation Analysis]
11 Bünger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375-389. [PMID: 21193998 DOI: 10.1007/s00432-010-0965-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis]
12 Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Arch Pathol Lab Med. 2014;138:220-228. [PMID: 24476519 DOI: 10.5858/arpa.2013-0056-oa] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19:3600-3610. [PMID: 23697990 DOI: 10.1158/1078-0432.ccr-12-3092] [Cited by in Crossref: 176] [Cited by in F6Publishing: 119] [Article Influence: 22.0] [Reference Citation Analysis]
15 Morgan TK, Hardiman K, Corless CL, White SL, Bonnah R, Van de Vrugt H, Sheppard BC, Grompe M, Cosar EF, Streeter PR. Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia. Cancer Cytopathol 2013;121:37-46. [PMID: 22811080 DOI: 10.1002/cncy.21223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Akinleye A, Iragavarapu C, Furqan M, Cang S, Liu D. Novel agents for advanced pancreatic cancer. Oncotarget 2015;6:39521-37. [PMID: 26369833 DOI: 10.18632/oncotarget.3999] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
17 Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017;109:djw266. [PMID: 28376157 DOI: 10.1093/jnci/djw266] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 16.5] [Reference Citation Analysis]
18 Li M, Zhao ZW. Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer. Med Oncol. 2012;29:970-976. [PMID: 21660619 DOI: 10.1007/s12032-011-9968-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
19 纪道林, 李春龙, 崔云甫. 胰腺癌早期诊断的研究进展. 世界华人消化杂志 2014; 22(17): 2406-2413 [DOI: 10.11569/wcjd.v22.i17.2406] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Gupta N, Yelamanchi R. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World J Gastroenterol 2021; 27(23): 3158-3181 [PMID: 34163104 DOI: 10.3748/wjg.v27.i23.3158] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 2012;118:5497-506. [PMID: 22569804 DOI: 10.1002/cncr.27592] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
22 Brezgyte G, Shah V, Jach D, Crnogorac-Jurcevic T. Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer-A Comprehensive Review. Cancers (Basel) 2021;13:2722. [PMID: 34072842 DOI: 10.3390/cancers13112722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liu D, Chang CH, Gold DV, Goldenberg DM. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Oncotarget 2015;6:4274-85. [PMID: 25595893 DOI: 10.18632/oncotarget.2760] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
24 Constantinou PE, Danysh BP, Dharmaraj N, Carson DD. Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab 2011;6:835-48. [PMID: 22201009 DOI: 10.1586/eem.11.70] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
25 Lin RS, Plevritis SK. Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. Cancer Causes Control 2012;23:175-85. [PMID: 22116537 DOI: 10.1007/s10552-011-9866-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
26 Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81:126-34. [PMID: 23026552 DOI: 10.1016/j.jprot.2012.09.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
27 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. J Immunol Res 2014;2014:268479. [PMID: 24818166 DOI: 10.1155/2014/268479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
29 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 836] [Article Influence: 137.7] [Reference Citation Analysis]
30 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 666] [Article Influence: 80.0] [Reference Citation Analysis]